Quest Diagnostics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quest Diagnostics (DGX).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

7Buy

8Hold

Consensus RatingNeutral# Analysts15Avg. Consensus PT$213Upside to Avg. PT-14.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$250→$260
Sep 21, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$250→$260
Sep 8, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$232→$245
Jul 28, 2026	JP Morgan	Lisa Gill	PT Raise	Neutral	$220→$250
Jul 24, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$220→$232
Jul 24, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$235→$260
Jul 24, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$225→$250
Jul 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$230→$250
Jul 24, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$236→$255
Jul 13, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$232→$236
Apr 22, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$210→$220
Apr 22, 2026	Baird	Eric Coldwell	PT Raise	Neutral	$224→$229
Apr 22, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$225→$230
Apr 22, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$220→$225
Apr 8, 2026	Evercore ISI Group	Elizabeth Anderson	PT Cut	In-Line	$220→$210
Feb 12, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$210→$235
Feb 11, 2026	Truist Securities	David Macdonald	PT Raise	Hold	$205→$220
Feb 11, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$190→$210
Feb 11, 2026	Evercore ISI Group	Elizabeth Anderson	PT Raise	In-Line	$190→$220
Feb 11, 2026	Barclays	Stephanie Davis	PT Raise	Overweight	$210→$225

Analyst Ratings News

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.

Benzinga Newsdesk

Quest Diagnostics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Quest Diagnostics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

PRO
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

People Also Watch

People Also Watch

Quest Diagnostics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Quest Diagnostics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

PROTruist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

PROUBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

PROJP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

PROMizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

PROTruist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

PRO
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

PRO
JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250

PRO
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260

PRO
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250